ProMIS Neurosciences (FRA:23J0) ROCE % : 369.97% (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is ProMIS Neurosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ProMIS Neurosciences's annualized ROCE % for the quarter that ended in Sep. 2024 was 369.97%.

ProMIS Neurosciences ROCE % Historical Data

The historical data trend for ProMIS Neurosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProMIS Neurosciences ROCE % Chart

ProMIS Neurosciences Annual Data

Trend

Mar14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-1,000.20

-116.61

-218.44

-542.56

ProMIS Neurosciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															-2,046.36	-224.78	-551.82	-	369.97

ProMIS Neurosciences ROCE % Calculation

ProMIS Neurosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-11.931	/	( ( (6.537 - 6.054)	+	(12.489 - 8.574) )	/ 2 )
	=	-11.931	/	( (0.483	+	3.915)	/ 2 )
	=	-11.931	/	2.199
	=	-542.56 %

ProMIS Neurosciences's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	33.432	/	( ( (1.31 - 2.947)	+	(22.084 - 2.374) )	/ 2 )
	=	33.432	/	( ( -1.637	+	19.71 )	/ 2 )
	=	33.432	/	9.0365
	=	369.97 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

ProMIS Neurosciences (FRA:23J0) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ProMIS Neurosciences ROCE % Related Terms

Thank you for viewing the detailed overview of ProMIS Neurosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ProMIS Neurosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProMIS Neurosciences Inc (FRA:23J0) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

PMN:USA 23J0:Germany

Address

1920 Yonge Street, Suite 200, Toronto, ON, CAN, M4S 3E2

Website

https://www.promisneurosciences.com

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

ProMIS Neurosciences Headlines

No Headlines